Imago is committed to developing true differentiating therapies, by focusing on eradicating stem cells responsible for myeloid malignancies. Our lead preclinical program is currently in IND-qualifying studies as a potential candidate for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and other diseases.
Myeloid malignancies, blood cell cancers arising in the bone marrow, have long been associated with disruptions of epigenetic regulation. There are many clinical versions of myeloid diseases, all of which can evolve to a life threatening stage. As with other cancers, several different types of agents may be needed to bring myeloid diseases under control.
One therapeutic strategy is to focus on those rare cancer cells that can divide indefinitely, so-called cancer stem cells. By targeting a cell that gives rise to many more, specifically, re-programming a cancer stem cell to behave like a normal cell offers great hope for the effective management of blood cancers.